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Role of CSC in cancer 
 CSCs are proposed to be exclusively capable of driving tumorigenesis because 
of: 
• Their ability for long-term self-renewal 
• Their capacity to differentiate into tumor bulk populations devoid of 
CSC features 
• Their unlimited potential for proliferation and tumorigenic growth 
 CSC can arise from mutations of normal stem cells, progenitor cells or more 
differentiated cells 
 Dysregulation of microenvironmental factors can contribute to the carcinogenic 
process 
 CSC exhibit increased resistance to chemotherapeutic agents 
 CSC are likely to drive tumor progression, tumor recurrence and metastasis 
 
 
  
Models of tumor heterogeneity CSC and metastasis 
Therapies 
Future views 
For more information 
 Tumors are composed of  heterogeneous cell populations 
 According to the stochastic model, all tumor cells are biologically 
equivalent, but their behavior is influenced by extrinsic and 
intrinsic factors. So, tumor-initiating activity can not be given to a 
specific group of cells 
 According to the hierarchy model, there are distinct classes of 
cells with different behavior in a tumor. Only a subset of them 
(CSCs) has the ability to initiate tumor growth 
Type of strategy Tumor in which has been proven 
Direct 
strategies 
CSC ablation 
Experimental models melanoma, liver 
cancer, glioma, breast cancer, human 
leukemia and bladder cancer 
Reversal of resistance of CSCs 
In vitro melanoma, CD133+ glioma CSC 
and breast cancer 
Differentiation therapy 
Experimental models of human glioma, 
breast cancer, acute myeloid leukemia 
Indirect 
strategies 
Antiangiogenic therapy 
Xenogratfs of human CD133+ glioma 
CSC 
Immunotherapetic approaches None at the moment 
 Current anticancer therapies are directed to proliferating cells 
assuming that all cells within a tumor have equal malignant 
potential 
 Cancer stem cells are not eradicated because of their 
chemoresistance and radioresistance 
 After therapy, CSCs survive and can reestablish the tumor 
 If therapies were directed against CSCs, then the other tumor 
cells will be unable to maintain the tumor, and it will 
degenerate 
 Several novel therapeutic strategies directed to CSCs are 
beginning to emerge, and are summarized in the following 
table: 
 
 Metastasis is the final step in the progression of malignancies 
 It is though that CSCs drive metastasis, as they are thought to be 
the unique cells with tumor-initiating ability: 
 CSCs of the primary tumor enter to the circulation 
trough EMT process (epithelial – mesenchymal 
transition), becoming circulating tumor cells (CTC) 
with stem cells features 
 These CTC remain in the circulation until they go to 
another organ and seed a new tumor 
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CSCs represent novel relevant targets for clinical cancer therapies, and the knowledge about this 
cells is still limited. It seems that patients cure without the efficient eradication of CSCs seems 
unreachable. Further research is needed, and if therapies were effective, they would be much mess 
toxic and more effective than current treatment modalities 
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